PortfoliosLab logoPortfoliosLab logo
Cronos Group Inc. (CRON)
Performance
Return for Risk
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN
CA22717L1013
CUSIP
22717L101
IPO Date
Jul 12, 2016

Highlights

EPS (TTM)
-$0.04
Total Revenue (TTM)
$193.36M
Gross Profit (TTM)
$62.76M
EBITDA (TTM)
$16.20M
Year Range
$1.60 - $3.43
Target Price
$2.30
ROA (TTM)
-0.79%
ROE (TTM)
-0.86%

Share Price Chart


Loading graphics...

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Cronos Group Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


Loading graphics...

S&P 500 Index

Returns By Period

Cronos Group Inc. (CRON) has returned -4.56% so far this year and 38.67% over the past 12 months.


Cronos Group Inc.

1D
2.87%
1M
-5.99%
YTD
-4.56%
6M
-9.71%
1Y
38.67%
3Y*
8.97%
5Y*
-23.23%
10Y*

Benchmark (S&P 500 Index)

1D
2.91%
1M
-5.09%
YTD
-4.63%
6M
-2.39%
1Y
16.33%
3Y*
16.69%
5Y*
10.18%
10Y*
12.16%
*Multi-year figures are annualized to reflect compound growth (CAGR)

Monthly Returns

Based on dividend-adjusted daily data since Jul 12, 2016, CRON's average daily return is +0.22%, while the average monthly return is +4.68%. At this rate, your investment would double in approximately 1.3 years.

Historically, 44% of months were positive and 56% were negative. The best month was Dec 2017 with a return of +133.8%, while the worst month was Oct 2018 at -33.3%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 9 months.

On a daily basis, CRON closed higher 45% of trading days. The best single day was Jul 15, 2016 with a return of +45.5%, while the worst single day was Aug 30, 2018 at -28.4%.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2026-4.56%6.37%-5.99%-4.56%
2025-5.94%7.89%-11.71%3.87%5.32%-3.54%3.66%31.31%6.92%-9.71%-1.59%6.48%30.20%
2024-4.31%4.00%25.48%12.64%-11.90%-10.04%5.15%-7.76%-3.10%-4.57%-0.48%-2.88%-3.35%
2023-0.79%-13.89%-10.60%-3.61%-6.42%12.57%-1.52%5.67%-2.44%-9.50%11.60%3.47%-17.72%
2022-5.87%-2.98%8.66%-22.37%-0.33%-6.31%11.70%-3.17%-7.54%17.38%-6.04%-18.33%-35.20%
202149.14%0.97%-9.47%-13.95%10.69%-4.55%-14.30%-10.31%-14.37%-8.30%-12.72%-13.47%-43.52%

Benchmark Metrics

Cronos Group Inc. has an annualized alpha of 49.89%, beta of 1.15, and R² of 0.08 versus S&P 500 Index. Calculated based on daily prices since July 13, 2016.

  • This stock captured 148.96% of S&P 500 Index gains but only 63.82% of its losses — a favorable profile for investors.
  • R² of 0.08 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

Alpha
49.89%
Beta
1.15
0.08
Upside Capture
148.96%
Downside Capture
63.82%

Return for Risk

Risk / Return Rank

CRON ranks 68 for risk / return — better than 68% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.


CRON Risk / Return Rank: 6868
Overall Rank
CRON Sharpe Ratio Rank: 6969
Sharpe Ratio Rank
CRON Sortino Ratio Rank: 7070
Sortino Ratio Rank
CRON Omega Ratio Rank: 6363
Omega Ratio Rank
CRON Calmar Ratio Rank: 7070
Calmar Ratio Rank
CRON Martin Ratio Rank: 6767
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

Return / Risk — by metrics

The table below present risk-adjusted performance metrics for Cronos Group Inc. (CRON) and compare them to a chosen benchmark (S&P 500 Index).


CRONBenchmarkDifference

Sharpe ratio

Return per unit of total volatility

0.84

0.90

-0.06

Sortino ratio

Return per unit of downside risk

1.62

1.39

+0.24

Omega ratio

Gain probability vs. loss probability

1.18

1.21

-0.03

Calmar ratio

Return relative to maximum drawdown

1.49

1.40

+0.10

Martin ratio

Return relative to average drawdown

3.01

6.61

-3.59

Explore CRON risk-adjusted metrics in detail

Dive deeper into individual metrics with historical trends, benchmark comparisons, and performance across different time periods.

Dividends

Dividend History


Cronos Group Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


Loading graphics...

Worst Drawdowns

The table below displays the maximum drawdowns of the Cronos Group Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Cronos Group Inc. was 93.16%, occurring on Apr 8, 2025. The portfolio has not yet recovered.

The current Cronos Group Inc. drawdown is 89.41%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-93.16%Mar 6, 20191533Apr 8, 2025
-51.36%Apr 11, 201750Jun 21, 201780Oct 13, 2017130
-50.55%Sep 21, 201827Oct 29, 201851Jan 14, 201978
-49.73%Jan 10, 201817Feb 2, 2018142Aug 27, 2018159
-29.63%Nov 21, 201625Dec 27, 20168Jan 9, 201733

Volatility

Volatility Chart

The chart below shows the rolling one-month volatility.


Loading graphics...

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Cronos Group Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Valuation

The Valuation section provides an overview of how Cronos Group Inc. is priced in the market compared to other companies in the Drug Manufacturers - Specialty & Generic industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PS Ratio

This chart shows the Price-to-Sales (P/S) ratio for CRON relative to other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, CRON has a P/S ratio of 3.3. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items